Prof Robin Foa speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about treatment alternatives to chemotherapy for leukaemia.
He explains that today there are many targeted treatments that are succesful, particularly with the help of minimal residual disease monitoring.
Prof Foa also highlights CAR-T as an area of excitement and a real step forward but that the treatment's high cost and restricted availability are current setbacks.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.